Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
450 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05560334 | A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05535647 | Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 |
| Sep 10, 2022 |
| clinicaltrials |
| NCT05036798 | Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System. | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT05524155 | Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Sep 1, 2022 | clinicaltrials |
| NCT05519410 | Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 29, 2022 | clinicaltrials |
| NCT05507593 | Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer | unknown | Phase 1 | 18 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05507606 | Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations | unknown | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05476380 | Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT05458180 | CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma | unknown | Phase 1 | 18 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 14, 2022 | clinicaltrials |
| NCT05273814 | Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer | unknown | Phase 1 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT05449483 | Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT04807673 | Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)(KEYSTONE-002) | recruiting | Phase 3 | 342 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05199168 | Visualization Versus Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerves During Thoracoscopic Esophagectomy | unknown | N/A | 120 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05392686 | PD1 and PARP for Maintenance Therapy in NSLLC | unknown | Phase 2 | 52 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT05356351 | An Open-label, Single-arm, Multicenter Phase II Clinical Study: Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 2, 2022 | clinicaltrials |
| NCT04903652 | Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer | completed | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT05167643 | H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study | unknown | N/A | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT04801459 | Study on the Peristaltic Direction of GI Anastomosis in Roux-en-Y Reconstruction | unknown | N/A | 148 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05251662 | Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05228743 | Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer | unknown | N/A | 180 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT05221775 | Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients | unknown | Phase 1 | 18 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 3, 2022 | clinicaltrials |
| NCT05166772 | Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy,HAIC)in the First-line Treatment of Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 22, 2021 | clinicaltrials |
| NCT05076097 | A Study of OLR in First-line Treatment of Mantle Cell Lymphoma | unknown | Phase 2 | 29 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 11, 2021 | clinicaltrials |
| NCT03861221 | The Technical Operations And Standard Clinical Application Protocol of CBBCT in Diagnostic Process of Breast Cancer(CBBCT) | completed | N/A | 800 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 29, 2021 | clinicaltrials |
| NCT05077839 | Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC(TOBACO) | unknown | Phase 2 | 184 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT05035147 | Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer | recruiting | Phase 4 | 934 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 21, 2021 | clinicaltrials |
| NCT05035381 | PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer | unknown | Phase 2 | 10 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT04982939 | Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer | unknown | Phase 2 | 210 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 31, 2021 | clinicaltrials |
| NCT04970264 | A Multicenter, Open and Observational Real World Study on the Prognosis and Treatment in Young Women With Breast Cancer | unknown | — | 2,000 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT04967976 | Breast Mesh Used in Two-staged Breast Reconstruction | unknown | N/A | 300 | Tianjin Medical University Cancer Institute and HospitalOTHER | 3 | Jul 20, 2021 | clinicaltrials |
| NCT04969029 | Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT04965831 | Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 16, 2021 | clinicaltrials |
| NCT04907344 | Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | unknown | Phase 2 / Phase 3 | 420 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 28, 2021 | clinicaltrials |
| NCT04814485 | Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 25, 2021 | clinicaltrials |
| NCT04900311 | Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer(Pyramid) | unknown | Phase 2 | 490 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 25, 2021 | clinicaltrials |
| NCT04884906 | Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT04828395 | Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer(F&C) | unknown | Phase 2 | 65 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 11, 2021 | clinicaltrials |
| NCT04882033 | Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer | unknown | Phase 1 | 9 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 11, 2021 | clinicaltrials |
| NCT04843215 | A Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric Cancer | recruiting | N/A | 950 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 10, 2021 | clinicaltrials |
| NCT04866381 | An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody | unknown | Phase 2 | 87 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 29, 2021 | clinicaltrials |
| NCT04846634 | Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)(ALTER-L043) | not yet recruiting | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT04825925 | Drug-eluting Beads Bronchial Arterial Chemoembolization in Stage II-III Non-small-cell Lung Cancer Patients Failed, Refused or Ineligible to Receive Standard Treatments | unknown | N/A | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Apr 12, 2021 | clinicaltrials |
| NCT04834986 | Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT04808687 | Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer | unknown | Phase 2 | 72 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 22, 2021 | clinicaltrials |
| NCT03736837 | Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC(ALTER-L004) | completed | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04797806 | Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC(SAINT) | unknown | Phase 3 | 206 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04782765 | Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma | unknown | Phase 2 | 59 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT04766827 | Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor | unknown | Phase 4 | 116 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04767828 | A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer | unknown | Phase 4 | 43 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04736186 | Prevention and Treatment of Pyrrolitinib-associated Diarrhea | unknown | Phase 2 / Phase 3 | 470 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 3, 2021 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials